Maxim Group analyst Jason McCarthy maintained a Buy rating on Capricor Therapeutics (CAPR) today and set a price target of $4. The company’s shares closed yesterday at $0.90, close to its 52-week low of $0.66.
McCarthy commented:
“Capricor reported 3Q18 with a net loss of ($4.1M) and ended the period with $10.4M in cash on the balance sheet, runway into 2Q18. We do expect that the company will need to raise capital in early 2019, prior to reaching data for the HOPE-2 study, which is expected in 2020.”
According to TipRanks.com, McCarthy is a 1-star analyst with an average return of -1.5% and a 30.2% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, ContraVir Pharmaceuticals Inc, and Sonoma Pharmaceuticals Inc.
The word on The Street in general, suggests a Hold analyst consensus rating for Capricor Therapeutics.
See today’s analyst top recommended stocks >>
Capricor Therapeutics’ market cap is currently $26.85M and has a P/E ratio of 44.76. The company has a Price to Book ratio of 2.79.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Capricor Therapeutics, Inc. engages in the discovery, development and commercialization of first-in-class biological therapies for the treatment of cardiac and other serious medical conditions. Its product candidate consists of CAP-1002, Cenderitide, Exosomes, CAP-1001, CU-NP and CSps.
